Black Diamond Therapeutics (BDTX) Profit After Tax (2018 - 2026)

Black Diamond Therapeutics (BDTX) has 9 years of Profit After Tax data on file, last reported at -$9.2 million in Q1 2026.

• Quarterly Profit After Tax fell 116.22% year-over-year to -$9.2 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was -$43.2 million (down 939.77% YoY) and the FY2025 annual result came in at $22.4 million, up 132.12% from the prior year.
• Profit After Tax grew to -$9.2 million in Q1 2026, from -$15.1 million in the prior quarter.
• In the past five years, Profit After Tax ranged from a high of $56.5 million in Q1 2025 to a low of -$25.5 million in Q1 2022.
• A 5-year average of -$13.3 million and a median of -$18.2 million in 2024 frame the typical range for Profit After Tax.
• Annual changes were most pronounced in 2025 — Profit After Tax soared 410.24% — and 2026, when it sank 116.22%.
• Tracing BDTX's Profit After Tax over 5 years: stood at -$19.0 million in 2022, then rose by 7.33% to -$17.6 million in 2023, then increased by 9.52% to -$15.9 million in 2024, then advanced by 5.13% to -$15.1 million in 2025, then soared by 39.32% to -$9.2 million in 2026.
• The last three Profit After Tax figures came in at -$9.2 million (Q1 2026), -$15.1 million (Q4 2025), and -$8.3 million (Q3 2025), per Business Quant data.